Axonis Therapeutics

Overview

Axonis Therapeutics is a Boston-based biotechnology company focused on developing innovative medicines for neurological disorders. The company specializes in targeting KCC2, a key mediator of inhibitory neurotransmission in the brain. Its mission is to restore functional inhibition in the central nervous system to address conditions like epilepsy and chronic pain, where existing therapies often fall short.

Founded on scientific discoveries from Boston Children’s Hospital, Harvard University, and Laval University, the organization utilizes a proprietary KCC2 discovery engine to create oral KCC2 potentiator drugs. Its lead candidate, AXN-027, is currently in first-in-human clinical trials and aims to improve treatment outcomes for patients by overcoming impaired synaptic inhibition. The company has secured substantial financial support, including a $115 million Series A financing round in October 2024, reflecting strong investor confidence in its technology and pipeline. It is committed to providing new treatment options for patients suffering from neurological disorders, particularly those with epilepsy and chronic pain.

Basic Information

Contact Details

• Website: axonis.us
• LinkedIn: linkedin.com/company/axonis-us

Key Focus Areas & Initiatives

• Drug discovery for neurological disorders
• KCC2 potentiator development
• Targeting impaired synaptic inhibition in epilepsy and chronic pain
• First-in-human clinical trials (AXN-027)
• Neuro-regeneration and neuroprotection research
• Innovative oral therapeutics
• Neuro-focused biotechnology development
• Animal models for CNS diseases
• Translational research from scientific discoveries

Technologies Used

• AI
• Google Font API
• IoT
• Microsoft Office 365
• Mobile Friendly
• Outlook
• Remote
• Shutterstock
• WordPress.org
• reCAPTCHA